Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples